The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Honoraria - Novartis
Consulting or Advisory Role - Novartis
Speakers' Bureau - Novartis
ReTHINK: A randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.
 
Francesco Passamonti
No Relationships to Disclose
 
Jean-Jacques Kiladjian
Honoraria - Novartis; Shire
Consulting or Advisory Role - Incyte; Novartis; Shire
Research Funding - AOP Orphan Pharmaceuticals (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Incyte; Novartis
 
Alessandro M. Vannucchi
Consulting or Advisory Role - Baxalta; Novartis
Speakers' Bureau - Novartis; Shire
Research Funding - Novartis (Inst)
 
Andreas Reiter
Honoraria - Novartis
Consulting or Advisory Role - Novartis
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Novartis
 
Savita Bharathy
Employment - Novartis
 
Dana Iommazzo
Employment - Novartis
 
Viktoriya Stalbovskaya
No Relationships to Disclose
 
Prashanth Gopalakrishna
Employment - Novartis
 
Ruben A. Mesa
Honoraria - AOP Orphan Pharmaceuticals; Novartis; shire
Consulting or Advisory Role - Baxalta; Galena Biopharma
Research Funding - CTI (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); NS Pharma (Inst); Pfizer (Inst); Pharmaessentia (Inst); Promedior (Inst)
Travel, Accommodations, Expenses - AOP Orphan Pharmaceuticals; Incyte; Novartis